Day One Biopharmaceuticals, Inc. (DAWN) has 20 既知のインサイダーおよび機関投資家保有者の記録. 最大保有者は Blavatnik Len 10,684,638 株保有. その他の主要保有者には Canaan XI L.P. および TAKEDA PHARMACEUTICAL CO LTD.
過去12ヶ月間にインサイダーは 43 件の取引を実施 DAWN 株式 — 14 件の買い (評価額 RSU アワード) および 13 件の売り (評価額 $839.84K). インサイダーの買いが売りを上回っており、会社の見通しに対する自信の表れかもしれません.
DAWN インサイダー保有状況
最大保有者
Blavatnik Len
10,684,638 株
インサイダー上位保有者
| # |
氏名 |
役職 |
保有株数 |
最終申告日 |
相対規模 |
| 1 |
Blavatnik Len |
Director |
10,684,638 |
2022-06-21 |
|
| 2 |
Canaan Xi L.p. |
10 Percent Owner |
6,964,301 |
2022-09-22 |
|
| 3 |
Takeda Pharmaceutical Co Ltd |
10 Percent Owner |
6,230,462 |
2021-12-09 |
|
| 4 |
Atlas Venture Fund Xi, L.p. |
Director |
6,008,534 |
2022-12-14 |
|
| 5 |
Blackman Samuel C. |
Head of R&d |
1,034,015 |
2024-12-12 |
|
| 6 |
Ai Day1 Llc |
10 Percent Owner |
827,586 |
2024-08-05 |
|
| 7 |
Atlas Venture Opportunity Fund I, L.p. |
Director |
793,116 |
2022-07-06 |
|
| 8 |
Atlas Venture Opportunity Fund Ii, L.p. |
10 Percent Owner |
766,667 |
2022-06-22 |
|
| 9 |
Atlas Venture Associates Opportunity I, Llc |
Director |
766,667 |
2022-06-22 |
|
| 10 |
Grant Papanek Julie |
Director |
439,358 |
2022-09-15 |
|
| 11 |
Grant Julie Papanek |
Director |
330,000 |
2023-03-03 |
|
| 12 |
Becker Daniel J. |
Director |
37,500 |
2023-06-26 |
|
| 13 |
Gladstone Michael |
Director |
32,335 |
2024-05-28 |
|
| 14 |
Merendino Lauren |
Chief Commercial Officer |
18,978 |
2026-02-18 |
|
| 15 |
Nicholson Garry A |
Director |
15,000 |
2025-06-04 |
|
| 16 |
Garland J. Scott |
Director |
15,000 |
2025-06-04 |
|
| 17 |
Holles Natalie C. |
Director |
15,000 |
2025-06-04 |
|
| 18 |
Grossman William |
Director |
15,000 |
2025-06-04 |
|
| 19 |
Ramasastry Saira |
Director |
15,000 |
2025-06-04 |
|
| 20 |
Josey John A. |
Director |
15,000 |
2025-06-04 |
|
最近の取引 (過去12ヶ月)
| 日付 |
氏名 |
役職 |
種類 |
株数 |
株価 |
価値 |
| 2026-02-17 |
Bender Jeremy |
Chief Executive Officer |
情報に基づく売り |
15,459 |
$11.60 |
$179.34K |
| 2026-02-15 |
Bender Jeremy |
Chief Executive Officer |
オプション行使（売却） |
4,750 |
- |
- |
| 2026-02-17 |
Merendino Lauren |
Chief Commercial Officer |
情報に基づく売り |
5,814 |
$11.60 |
$67.45K |
| 2026-02-15 |
Merendino Lauren |
Chief Commercial Officer |
オプション行使（売却） |
3,162 |
- |
- |
| 2026-02-17 |
Dubow Adam |
Gen Counsel & Secretary |
情報に基づく売り |
6,395 |
$11.60 |
$74.19K |
| 2026-02-15 |
Dubow Adam |
Gen Counsel & Secretary |
オプション行使（売却） |
1,750 |
- |
- |
| 2026-02-17 |
Vasconcelles Michael |
Head of Research and Dev. |
情報に基づく売り |
2,728 |
$11.60 |
$31.65K |
| 2026-02-15 |
Vasconcelles Michael |
Head of Research and Dev. |
オプション行使 |
7,125 |
- |
- |
| 2026-02-17 |
York Charles N Ii |
COO and CFO |
情報に基づく売り |
6,065 |
$11.60 |
$70.36K |
| 2026-02-15 |
York Charles N Ii |
COO and CFO |
オプション行使（売却） |
2,250 |
- |
- |
| 2026-01-30 |
Bender Jeremy |
Chief Executive Officer |
RSU 付与（制限付株式） |
237,000 |
- |
- |
| 2026-01-30 |
Merendino Lauren |
Chief Commercial Officer |
RSU 付与（制限付株式） |
74,000 |
- |
- |
| 2026-01-30 |
Dubow Adam |
Gen Counsel & Secretary |
RSU 付与（制限付株式） |
70,000 |
- |
- |
| 2026-01-30 |
Vasconcelles Michael |
Head of Research and Dev. |
RSU 付与（制限付株式） |
114,000 |
- |
- |
| 2026-01-30 |
York Charles N Ii |
COO and CFO |
RSU 付与（制限付株式） |
126,000 |
- |
- |
| 2025-11-25 |
Bender Jeremy |
Chief Executive Officer |
贈与（送付） |
7,225 |
- |
- |
| 2025-11-17 |
Bender Jeremy |
Chief Executive Officer |
情報に基づく売り |
15,894 |
$8.91 |
$141.69K |
| 2025-11-15 |
Bender Jeremy |
Chief Executive Officer |
オプション行使（売却） |
3,570 |
- |
- |
| 2025-11-17 |
Merendino Lauren |
Chief Commercial Officer |
情報に基づく売り |
3,726 |
$8.91 |
$33.22K |
| 2025-11-15 |
Merendino Lauren |
Chief Commercial Officer |
オプション行使（売却） |
3,162 |
- |
- |
| 2025-11-17 |
Dubow Adam |
Gen Counsel & Secretary |
情報に基づく売り |
4,319 |
$8.91 |
$38.5K |
| 2025-11-15 |
Dubow Adam |
Gen Counsel & Secretary |
オプション行使（売却） |
1,750 |
- |
- |
| 2025-11-17 |
York Charles N Ii |
COO and CFO |
情報に基づく売り |
4,062 |
$8.91 |
$36.21K |
| 2025-11-15 |
York Charles N Ii |
COO and CFO |
オプション行使（売却） |
1,375 |
- |
- |
| 2025-11-06 |
Bender Jeremy |
Chief Executive Officer |
株式返還 |
286,000 |
$11.87 |
$3.39M |
